AMG-193 is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMG-193’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMG-193 is under development for treatment of metastatic or advanced methylthioadenosine phosphorylase (MTAP) null non-small cell lung cancer, MTAP-null squamous non-small cell lung cancer and metastatic or advanced MTAP null solid tumors including bile tract cancer, pancreatic cancer, brain tumor, head and neck cancer squamous cell carcinoma, lymphoma. The drug candidate is administered orally as tablet. It acts by targeting protein arginine N-methyltransferase 5 (PRMT5).
It was also under development for bile duct cancer.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of AMG-193’s drug-specific PTSR and LoA scores, buy the report here.